Status:
UNKNOWN
Influence of Nebivolol on Postmenopausal Women
Lead Sponsor:
Medical University of Vienna
Conditions:
Hot Flashes
Heart Rate
Eligibility:
FEMALE
Brief Summary
After menopause the coronary artery disease (CAD) risk increases rapidly to an equivalent risk of men with the same age. The rising incidence of CAD could be a subsequent decline of endogenous estroge...
Detailed Description
1. Background CAD is the leading cause of mortality for women in US as well as in Austria and most developed countries. Major risk factors are hypertension, diabetes and the postmenopausal sta...
Eligibility Criteria
Inclusion
- Menopausal patients (estrogen \<20 pg/ml and FSH \>35 mIU/ml)
- The patients are sexually active
- The patients have hot flushes
- The patients have palpitations or extrasystoles
Exclusion
- Contraindications for a beta-blocker therapy such as:
- Patients with COPD
- Patients with an AV-block
- Patients with a bradycardia (meaning a heart rate \<50 beats per minute)
- Patients with hypotension (RR \<100/80 mmHg)
- Patients with a PAD (stage III, IV)
- Patients with Asthma
- Patients with Morbus Raynaud
- Patients with a carcinoma
- Patients, who have already been treated because of hypertension
- Patients, who receive hormone replacement therapy
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01161823
Start Date
January 1 2010
Last Update
January 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, Medical University of Vienna
Vienna, Vienna, Austria, 1090